Dr Deepak Singhal

MBBS, MD, FRACP, FRCPA
Clinical Haematologist
Make an Appointment

Dr Deepak Singhal is passionate about providing the best possible care for his patients, supporting them from diagnosis, through to treatment and into survivorship.

Biography

Dr Deepak Singhal is an experienced clinical haematologist at Icon Cancer Centre Adelaide and Icon Cancer Centre Windsor Gardens. He completed medical studies and haematology training in India before relocating to Adelaide in 2008. Dr Singhal subsequently completed an acute myeloid leukaemia/myelodysplastic (AML/MDS) fellowship at the Royal Adelaide Hospital (RAH) and holds dual fellowships to the Royal Australasian College of Physicians (FRACP) and Royal College of Pathologists of Australasia (FRCPA).

Dr Singhal maintains an active interest in national and international research into the diagnosis and management of haematology conditions and played an instrumental role in the expansion of the South Australian Myelodysplastic Syndrome Registry (SA-MDS). He currently holds appointments as a clinical and laboratory haematologist and transplant physician at the RAH, co-lead of the CALHN AML/MDS stream, member of the MDS research group at the South Australian Medical and Research Institute (SAHMRI) and clinical associate lecturer at the University of Adelaide.

Dr Singhal is a member of several leading cancer trial groups and has published clinical research articles in the American Journal of Haematology, Haematologica and Leukaemia. He is also a regular invited speaker at national and international haematology conferences. Throughout his haematology career Dr Singhal has been a recipient of several awards and grants including the American Society of Hematology Abstract Achievement Award (2015, 17-18), Haematology Society of Australia and New Zealand Educational Grant (2016) and Travel Grant (2017), RAH Research Fund Simpson Prize for Cancer Research (2020) and AR Clarkson Scholarship (2016).

Dr Singhal is experienced in caring for a wide range of malignant and non-malignant haematology conditions including deranged blood counts, myeloid disorders, lymphoid disorders, paraproteinaemia, myeloma, clotting and bleeding disorders and stem cell transplantation. He is passionate about improving the outlook of all types of haematology conditions by engaging with patients, caregivers, medical professionals and researchers and considers himself fortunate to work alongside a dedicated team of clinicians, nursing and support staff and researchers. Outside of haematology, he enjoys weekend hiking, cycling and spending time with his wife and young children.

Affiliations & Memberships

  • American Society for Transplantation and Cellular Therapy (ASTCT)
  • American Society of Haematology (ASH)
  • Australasian Leukaemia and Lymphoma Group (ALLG)
  • European Hematology Association (EHA)
  • Haematology Society of Australia & New Zealand (HSANZ)
  • Royal Australasian College of Physicians (RACP)
  • Royal College of Pathologist of Australasia (RCPA)

Special Interests

Dr Deepak Singhal accepts referrals for malignant and non-malignant blood disorders, with a special clinical interest in:
  • Lymphoma
  • Multiple myeloma
  • Myeloproliferative neoplasms
  • Stem cell transplantation
  • Thrombosis and haemostasis

Icon Locations

Adelaide (Kurralta Park) View centre
Adelaide (Windsor Gardens) View centre

Publications

  • Cerebrospinal fluid zinc, magnesium, copper and gamma-aminobutyric acid levels in febrile seizures. O.P. Mishra, D. Singhal, R.S. Upadhyay, R. Prasad & D. Atri. Journal of Pediatric Neurology, 2007; 5(1):39-44.

  • Twelve years of experience of acquired hemophilia A: trials and tribulations in South Australia. Tay, E. Duncan, D. Singhal, R. Al-Qunfoidi, D. Coghlan, W. Jaksic, F. Szabo, S. McRae & J. Lloyd. Seminars in thrombosis and hemostasis, 2009; 35(8):769-777.

  • Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome. Singhal, M.M. Kutyna, R. Chhetri, L.Y. Wee, S. Hague, L. Nath, S.V. Nath, R. Sinha, N. Wickham, I.D. Lewis, D.M. Ross, P.G. Bardy, L.B. To, J. Reynolds, E.M. Wood, D.J. Roxby & D.K. Hiwase. Haematologica, 2017; 102(12): 2021.

  • Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients. K. Hiwase, D. Singhal, C. Strupp, R. Chhetri, M.M. Kutyna, L.A. Wee, P.B. Harrison, S.V. Nath, N. Wickham, C. Hui, J.X. Gray, P. Bardy, D.M. Ross, I.D. Lewis, J. Reynolds, L.B.To, U. Germing. American Journal of Haematology, 2017; 92(6):508-514.

  • The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution. Singhal, L.A. Wee, M.M. Kutyna, R. Chhetri, J. Geoghegan, A.W. Schreiber, J. Feng, P. Wang, M. Babic, W.T. Parker, S. Hiwase, S. Edwards, S. Moore, S. Branford, T. Kuzmanovic, N. Singhal, R. Gowda, A.L. Brown, P. Arts, L.B. To, P.G. Bardy, I.D. Lewis, R.J. D’Andrea, J.P. Maciejewski, H.S. Scott, C.N. Hahn & D.K. Hiwase. Leukaemia, 2019; 33(12): 2842-2853.

View all

Search